Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.

The oncologist - 1 Dec 2025

Wheless Margaret C, Stockton Shannon, Soares Heloisa P, Dayyani Farshid, Saeed Anwaar, Kim Edward, Jin Ning, Yacoub George, Florou Vaia, Ayers Gregory D, Guerrouahen Bella S, Contreras Alejandro, Li Li, Ferry-Galow Katherine V, Gore Steven, Das Satya, Berlin Jordan

Abstract excerpt

BACKGROUND: Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage induced by cytotoxic chemotherapy. We aimed to assess the efficacy of ATR inhibitor, berzosertib, with irinotecan in patients harboring TP53-mutated, metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Irinotecan

Share to Isoxazoles

Share to Pyrazines

Share to Pyrazoles

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41335461
DOI: 10.1093/oncolo/oyaf400
PMCID: PMC12718112

Genes

TP53
ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.PMID 41335461Read ↗

Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal CancerSemantic proximity Read ↗

Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.Semantic proximity Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Semantic proximity Read ↗

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read ↗

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Semantic proximity Read ↗

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response DefectsSemantic proximity Read ↗

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid TumorsSemantic proximity Read ↗

The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Semantic proximity Read ↗

KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib studySemantic proximity Read ↗

A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers.Semantic proximity Read ↗

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.Semantic proximity Read ↗

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.